FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Roche

Roche's CellCept linked to birth defects

Tools

The FDA is warning doctors and patients that CellCept, a drug for organ transplant patients, can cause miscarriages and birth defects. Made by Roche, CellCept will get a "black box" warning that it's been linked to first-trimester pregnancy loss and ear and mouth defects in infants.

Roche cited 25 miscarriages among 77 women exposed to the drug during pregnancy between 1995 and 2007; 14 of the women had babies with birth defects. However, to put this in perspective, more than 450,000 men and women have taken the drug since its 1995 approval.

- read the Houston Chronicle article for more

Related Articles:
Aspreva, Roche put CellCept on ice. Report
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report

More stories about FDA   Roche  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.